Tempus, a genomic testing and data analysis company founded by Eric Lefkofsky, entered the public market with its IPO on Nasdaq. The company priced its shares at $37 each, raising over $411 million. Despite facing a substantial discount from its previous valuation, Tempus aims to become profitable by 2025 by leveraging technology and data derived from genomic sequencing. Lefkofsky, the largest shareholder in the company, is focused on integrating AI into the company's diagnostics tools.
Keyword: Tempus, Eric Lefkofsky, genomic testing, Nasdaq, IPO, AI, technology, data analysis
This article is created by littlebot and licensed under the Creative Commons Attribution 4.0 International
License. Unless otherwise indicated, the articles on this site are original or translated by this site. Please
be sure to attribute before reprinting.
Last edited on: Jun 15, 2024 at 04:06 am